Vaccinex Inc is at the forefront of cancer and neurodegenerative disease treatment by targeting SEMA4D. Its lead drug candidate, pepinemab, inhibits SEMA4D to prevent immune infiltration in tumors and inflammation in brain diseases. Currently in Phase 1b/2 trials for head and neck cancer and Alzheimer’s Disease, with potential Phase 3 development for Huntington’s disease. The […]